News & Updates

Men with anxiety disorder commonly suffer from concomitant erectile dysfunction, according to a recent systematic review.

The coronavirus disease 2019 (COVID-19) pandemic has caused the postponement of several sexual and reproductive health surgeries, which in turn leads to severe restrictions in the patients’ private lives and aggravates their worries about their disease, a recent study has found.

Between 2009 and 2019, Google searches regarding erectile dysfunction (ED) across the United States peak during winter, hinting at a potential seasonal dimension of ED, a recent study has found.

For men with erectile dysfunction (ED) who show a lack of response to oral phosphodiesterase type 5 inhibitors (PDE5Is), combination therapy with topical alprostadil plus PDE5Is seems favourable, producing greater improvements in sexual function without compromising safety compared with topical alprostadil alone, as shown in a study.

Patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) who have been initiated on apalutamide in a real-world setting appear to show prostate-specific antigen (PSA) response that is strong and consistent with that reported in clinical trials, as reported in a study.

The combination of olaparib and abiraterone in the first-line setting improved radiographic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (mCRPC), results of the phase III PROpel trial showed.